PT  - JOURNAL ARTICLE
AU  - SCHMIDINGER, MANUELA
AU  - BOJIC, ANDJA
AU  - VOGL, URSULA M
AU  - LAMM, WOLFGANG
AU  - ZIELINSKI, CHRISTOPH C.
TI  - Management of Cardiac Adverse Events Occurring with Sunitinib Treatment
DP  - 2009 May 01
TA  - Anticancer Research
PG  - 1627--1629
VI  - 29
IP  - 5
4099  - http://ar.iiarjournals.org/content/29/5/1627.short
4100  - http://ar.iiarjournals.org/content/29/5/1627.full
SO  - Anticancer Res2009 May 01; 29
AB  - Background: Sunitinib malate is the reference standard of care for the first-line treatment of metastatic renal cell carcinoma (mRCC). Cardiovascular adverse events (AEs) have been observed with sunitinib treatment. Here, we present the case report of a 49-year-old male patient with mRCC in whom cardiac AEs experienced during sunitinib treatment were successfully managed. The patient was at poor prognostic risk, with an Eastern Cooperative Oncology Group performance status of 3. Results: The patient was treated with sunitinib 50 mg/day (4 weeks on treatment followed by 2 weeks off treatment; Schedule 4/2) following lung and bone metastases. Cardiac AEs occurred following sunitinib initiation. These events were resolved with cardiovascular co-medication. Sunitinib improved the patient's quality of life and performance status, with a prolonged duration of treatment of 24 months. Conclusion: This case indicates that cardiac AEs should not be a barrier to the effective use of sunitinib in mRCC.